Printer Friendly

Biotech Holdings Foresees Potential Sales Exceeding $100 Million US from Mexico Licensing Agreement.

Business Editors

VANCOUVER, British Columbia--(BUSINESS WIRE)--March 21, 2001

Robert Rieveley, President of Biotech Holdings ("Biotech") (OTCBB:BIOHF) (CDNX:BIO.V) (Frankfurt:925970.F), announced today that the Company has forwarded a registration dossier to its new licensee for the Mexican market, Micrometrix s.a. de CV of Mexico City.

"A complete regulatory application has been forwarded to our licensee, Micrometrix, for submission to Mexican regulators," Rieveley said.

"Micrometrix is an aggressive, entrepreneurial pharmaceutical company with a history of double-digit sales growth. Mexico, with its 100-million population, is the twelfth largest pharmaceutical market in the world and a has the potential to become an important market for DIAB II. With over three million diabetics and health care spending on Type II Diabetes rising steadily, we can foresee that the value of DIAB II sold in the Mexican market could grow to exceed $100 million US over the course of our seven-year licensing agreement," Rieveley said.

"We are particularly pleased to be working with the founder of Micrometrix, Pedro Tomas Martin. Mr. Martin is a past president of the Chemical Pharmaceutical Production Association of Mexico and a member of various bodies within the Mexican Pharmaceutical Association. He also has extensive production experience including positions as Production Manager for Bristol Myers Squibb Mexico and plant manager for Miles Laboratories, prior to his founding of Micrometrix in 1977, and has participated in the setting of Good Manufacturing Practice (GMP) standards and procedures for the Mexican pharmaceutical industry," Rieveley said.

"Micrometrix currently manufactures for several multi-national pharmaceutical companies. We believe that the extensive regulatory experience that Micrometrix brings to our partnership will be invaluable for guiding our DIAB II regulatory application and that our partner's manufacturing capabilities will enhance our prospects for a timely launch of DIAB II in Mexico," Rieveley said.

DIAB II is an insulin-receptor sensitizer, a new class of drugs for controlling the chronically high blood sugar levels that typify diabetes. DIAB II, in tablet form, works by improving the patient's ability to utilize insulin, the hormone that controls blood sugar levels. The Company currently markets DIAB II in China as a prescription treatment of Type II Diabetes and has licensees for DIAB II in Brazil, Argentina, Chile, Peru and Venezuela. Earlier this year, the Company filed a regulatory application for DIAB II in Peru. Type II Diabetes affects more than 17 million people in North America, over 20 million in Latin America and over 150 million worldwide.

Biotech Holdings Ltd. is based in Vancouver, British Columbia and has its laboratory and plant facility in Richmond, B.C. For inquiries, contact Austin Rand at Biotech Holdings Ltd., 888/216-1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.

This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions. These forward-looking statements represent the Company's best judgement at the date of this release and any changes in assumptions or external factors could produce significantly different results.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 21, 2001
Words:571
Previous Article:WebQuote Demonstrates SalesLINK Software Platform at PCB West 2001.
Next Article:Genesys Telecommunications Licenses Worldwide Rights to GLOBEtrotter's Electronic Licensing Technology; Software Industry Continues Rapid...
Topics:


Related Articles
NAFTA won't siphon off U.S. jobs, corporate executives say.
Providing international assistance to members.
Molecular Sex for Fun and Profit.
AMGEN ENDS TWO LICENSING PACTS.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters